Abstract To prospectively evaluate the long-term clinical safety and efficacy of a newly designed selfexpanding metallic stent (SEMS) in the treatment of patients with achalasia. Seventy-five patients with achalasia were treated with a temporary SEMS with a 30-mm diameter. The SEMSs were placed under fluoroscopic guidance and removed by gastroscopy 4-5 days after stent placement. Follow-up data focused on dysphagia score, technique and clinical success, clinical remissions and failures, and complications and was performed at 6 months, 1 year, and within 3 to 5 years, 5 to 8 years, 8 to 10 years, and >10 years postoperatively. Stent placement was technically successful in all patients.
Introduction
Pneumatic dilation (PD) is considered the first-line therapy for esophageal achalasia in many institutions [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] since remission can be achieved in 60 to 90% of the patients [12, 13] . However, this therapeutic strategy remains controversial since long-term remission rates after PD have been reported to drop progressively with time, from 20% to 61% at 10 years [2, 4, 7, 8, 10, 14] , especially in young subjects [10] , leading some authors to consider surgery as an alternative option.
Self-expanding metallic stents (SEMS) have been the most common form of palliative treatment of patients with malignant esophageal dysphagia and/or esophagorespiratory fistulas for the last 2 decades [15] [16] [17] [18] [19] [20] . However, the use of esophageal stents in benign esophageal conditions has been considered to be relatively contraindicated because of concerns about an increased risk of complications, such as stent migration, reflux, perforation, bleeding, and, most importantly, new strictures caused by stentinduced tissue hyperplasia [21] [22] [23] [24] [25] [26] [27] .
Recently, this traditional view has begun to change, and a number of case reports or small series of data presentations have suggested the feasibility of stent placement in the cardiac esophagus [28] [29] [30] [31] [32] [33] . Since July 1994, we have used the placement of a new, specially designed self-expandable metallic stent (Youyan Yijin Advanced Materials Co., Ltd., Beijing, China) in the distal esophagus. The purpose of this study was to prospectively evaluate the long-term clinical safety and efficacy of a newly designed SEMS with a 30-mm diameter in the treatment of patients with esophageal achalasia.
Materials and methods

Study design
This pilot study was approved by the Institutional Review Board at The Sixth Affiliated People's Hospital of Shanghai Jiao Tong University, and informed consent was obtained from each patient. From July 1994 to December 2007, we performed a prospective study of fluoroscopical placement of a SEMS in patients with primary esophageal achalasia. The inclusion criteria for stent placement were as follows: (1) documented primary esophageal achalasia; (2) recurrent dysphagia following pneumatic balloon dilation; (3) patient life expectancy of more than 6 months. The exclusion criteria were (1) a lesion longer than 6 cm; (2) presence of dysfunction of blood coagulation, active infection, significant cardiac or pulmonary disease, malignancy, and significant psychological or psychosocial dysfunction; (3) World Health Organization (WHO) performance score ≥3. The preoperative diagnosis was based on clinical presentation, barium swallow, gastroscopy, or esophageal manometry. These procedures were performed by an interventional radiologist (Y.S.C.) who had 15 years of experience in gastrointestinal interventional radiology.
Patients were evaluated before and immediately after stent placement, at 3 months, 6 months, and then every 6 months after stent removal until death. The evaluations before placement of the metal stent were performed by three radiologists participating in the study. Postoperative regular follow-up was performed by responses to a standardized questionnaire for symptoms by telephone or outpatient clinic interview, barium swallow, and, if necessary, endoscopy. Parameters evaluated during followup included: (1) WHO performance status (0 = normal activity, 1 = symptoms but ambulatory, 2 = in bed less than 50% of time, 3 = in bed more than 50% of time, and 4=100% bedridden); (2) dysphagia score (grade 0, no dysphagia; grade 1, some solid food; grade 2, can swallow liquids only; grade 3, difficulty with liquids and saliva; grade 4, complete dysphagia); (3) outcomes (technical and clinical success, 30-day mortality, clinical remission or failures, dysphagia score and WHO performance status, survival, and cause of death); (4) complications and recurrent dysphagia; (5) specific symptoms, such as substernal pain, heartburn, regurgitation, and fever. All evaluation items were recorded in a case record form. Prospective data collection focused on dysphagia score, technical and clinical outcome, clinical remission or failures, and specific symptoms.
Stent construction and insertion procedure
The self-expandable metallic stent was woven from a single thread of 0.16-mm highly elastic nitinol wire with a good histocompatibility and memory. On the one hand, the stent could expand to its expected and maximal diameter at body temperature; on the other hand, the stent could shrink and become soft at cold temperatures. The stent had a tubular configuration as shown in Fig. 1 . The body of the stent covered with polyethylene was 30 mm in diameter and 60-80 mm in length when fully expanded. Three radiopaque markers made of gold wire attached at both ends and in the middle of the body part facilitated precise placement of the stent. The stents were constructed by a manufacturer (Youyan Yijin) according to our specifications. For implantation under fluoroscopic guidance, the stent was mounted in a compressed state on the guiding tube by the introducer sheath 24 Fr (8 mm) in diameter.
The self-expandable metallic stent was developed by both our institute and the Youyan Yijin Advanced Materials Cooperation (Youyan Yijin). It was specifically designed for placement of the stent in the esophageal cardia. Topical anesthesia of the pharynx using an aerosol spray was routinely performed before the procedure, and sedative drugs were not used. Details of the stent placement techniques are provided elsewhere [28, 29] . In brief, prior to the procedure, a water-soluble contrast swallow (Ultravist 300; Schering, GuangZhou, China) was used to indicate the proximal and distal borders of the esophageal achalasia. After topical anesthesia (lidocaine 2%), a 0.035-inch guide wire (Radiofocus M; Terumo, Tokyo, Japan) with a straight 5-Fr catheter (Torcon NB; Cook, Bloomington, IN) was advanced perorally until the tip reached the gastric body and then exchanged for a stiffer one (0.035-inch Amplatz super-stiff). A 24-Fr delivery system (Youyan Yijin) was inserted over the guide wire until the proximal and distal edges of the stent bridged the esophageal achalasia under fluoroscopic control, and the stent was then deployed by pulling back the introducer sheath. Correct placement of the stent and satisfactory achalasia coverage were confirmed by contrast-enhanced fluoroscopy with peroral administration of water-soluble contrast (Ultravist) after deploying the stent. Patients ate semisolid food on the day after stent placement and were given prophylactic H 2 receptor blockade to prevent reflux esophagitis.
Retrieval of the stent was performed with the help of a gastroscopy 3-7 days after stent placement. First, 500-1,000 ml of ice-cold water was injected via the bioptic hole to retract the stent, and then the stent was grasped by the retrieval lasso or the proximal stent wire and gently pulled out. Usually less than 10 min was required for this procedure. Gastroscopy and esophageal radiography were performed immediately after removal of the stent to rule out possible complications, such as bleeding, perforation, etc.
Postoperative outcome evaluation
Technical success was defined as successful insertion of the stent into the esophageal achalasia without any major complications, such as esophageal rupture or massive bleeding. Clinical success was defined as the symptomatic improvement in dysphagia and good esophageal emptying on esophagography 1 month after removal of the stent. Primary patency was defined as the time interval from stent remove to clinical failure without subsequent stent placement or balloon dilation.
Complications, including esophageal perforation, chest pain, and reflux, were evaluated. Esophageal perforation was defined as contrast leakage from the esophageal lumen on immediate esophagography or pneumomediastinum or pneumoperitoneum on immediate chest radiograph. Severe pain was defined as pain that developed after stent placement requiring narcotic analgesics. Gasotroesophageal reflux was defined as contrast reflux through the gasotroesophageal junction, as confirmed by follow-up esophagography.
All patients were followed up as outpatients for a mean of 4.01±3.18 years (range: 0.5-11.8 years). Outcome assessment was performed at 6 months, 1 year, and within 3 to 5 years, 5 to 8 years, 8 to 10 years, and >10 years postoperatively. The clinical follow-up evaluation was focused on dysphagia, regurgitation, heartburn, and substernal pain. The incidence of each symptom was graded according to the proposal by Johnson and De Meester [34] as follows: grade 0, absence of the symptom; grade 1, occasional episodes of the symptom reported to occur less than once weekly; grade 2, frequent episodes of the symptom reported to occur more than once weekly; grade 3, persisting daily symptoms. To estimate the effectiveness of treatment, the following grading system was used: A score of 0 to 2 was considered excellent, 3 to 5 was considered good, 6 to 8 was considered fair, and 9 to 12 was considered poor. Excellent/good results were considered as clinical remission, whereas fair/poor results were clinical failures. Patients with poor results were candidates for subsequent balloon dilation or stent placement.
Statistical analysis
All the data were expressed as the mean ± SD. Comparisons of pre-and postprocedure dysphagia score between the two groups were performed by applying the Mann-Whitney test. The curve of primary patency was calculated according to the Kaplan-Meier method. Statistical analyses were performed using SPSS statistical software (version 13.0 for Windows, SPSS Inc., Chicago, IL). A p value < 0.05 was considered significant.
Results
Demographics
The characteristics of the patient population in this study are summarized in Table 1 . A total of 75 patients who underwent stent placement for achalasia during the 13-year study period were enrolled in the analysis. These included 36 men and 39 women with a mean age of 36.36± 12.33 years (range: 12-72 years). The mean time interval between a significant dysphagia confirmation and stent placement was 5.23±3.49 years (ranging from 1.1-14.6 years). Current symptoms were dysphagia (n=75, 100%), chest pain (n=47, 71%), regurgitation (n=37, 23%), and heartburn (n=28, 23%), with a mean weight loss of 3.42±3.07 kg (range: 0.3-12.6 kg). The mean dysphagia score before stent placement was 2.8±0.52. The mean diameter of the narrowest region of the cardia was 5. Stent migration occurred in four (5.33%) patients, and all of them needed a second stent placement 2-4 days after stent placement. Twenty-eight (38.7%) patients complained of chest pain within 5 days after stent placement, in which two required analgesics for severe pain. Reflux and bleeding (after stent removal) were observed in 15 (20%) and 9 (12%) patient, respectively, both of which were alleviated or disappeared spontaneously following stent removal without additional treatment. No perforation or food impaction occurred in our series after stent placement, and there was no 30-day mortality.
The clinical symptoms of dysphagia resolved in all patients, and all patients were able to swallow satisfactorily within 24 h after successful stent placement. The average time from SEMS placement to stent removal was 4 to 5 days. Clinical success was achieved in all patients with patency of the distal esophagus 1 month after stent removal, and the dysphagia score significantly improved for all patients, with a median score of 2.8± 0.52 before stent placement to a median score of 0.19± 0.39 (P<0.001).
Long-term follow-up and final outcome
The long-term follow-up and clinical outcome following stent treatment at different follow-up time points are shown in Table 1 . The mean time from stent removal to last follow-up assessment was 4.01±3.18 years (range: 0.5-11.8 years). All patients were followed up and assessed at 6 months and 1 year, 66 were assessed for 1-3 years, 33 were assessed for 3-5 years, 24 were assessed for 5-8 years, 13 were assessed for 8-10 years, and 6 were assessed for more than 10 years, prospectively.
Follow-up evaluation at 3 months and 1 year postoperatively At 6 months postoperatively, the mean dysphagia score of 0.23±0.38 decreased significantly compared with the mean preoperative value 2.8±0.52 (P<0.001). The mean dysphagia score at the 1-year postoperative follow-up evaluation was 0.25±0.45 with an overall excellent and good successe rate of 96%. None of the patients exhibited dysphagia relapse during a 6-month follow-up, and 3 patients out of 75 exhibited dysphagia relapse during a 6-12-month follow-up.
Long-term follow-up evaluation
The overall mean symptom score at the 1−, 3−, 5−, 8−, and >10-year follow-up remained significantly lower than the preoperative values. The cumulative clinical remission rates at 1-3, 3-5, 5-8, 8-10, and >10 years after stent removal for achalasia were 93.9%, 90.9%, 100%, 100%, and 83.3%, respectively (Figs. 2 and 3) .
Within the 13-year follow-up period, stent treatment was considered to have failed in six patients after a median follow-up period of 3.18±3.83 years (range 0.6-10.4 years), and the overall cumulative success rate in our series was 92%. Four patients continued to be followed up due to mild recurrent dysphagia, and the remaining two decided to undergo Heller myotomy and were excluded from this study. None of the patients died at the end of this report.
Cessation of primary patency occurred in six patients as a result of recurrence. The median and mean primary patency was 2.8±0.28 years (95% CI: 2.25-3.35) and 4.28±0.40 years (95% CI: 3.51-5.05), respectively.
Discussion
Treatment of achalasia with the use of SEMS, originally used as a last resort in patients who had failed medical therapy or pneumatic dilation, or who were poor surgical candidates, was first described by De Palma in 1998 with encouraging results [33] . To date, only a few reports in the English literature describe treating achalasia with the use of SEMS [23, 27, 32, 33] . Although the management of benign esophageal strictures with stent placement is becoming better established, some authors do not recommend using EMS in achalasia because of poor results and complications [23, 27, 32] . However, we believe that temporary SEMSs are helpful in the treatment of achalasia [28] [29] [30] [31] . These long-term results suggest that treatment of achalasia with the use of SEMS is safe and feasible.
The new large-sized, temporary SEMS has two unique advantages over the conventional, permanent, small-sized stent and pneumatic dilatation: (1) it provides long-term good clinical symptomatic remission of dysphagia with one session of stent placement; (2) it maximally decreases the risk of complications, such as stent migration, perforation, and new strictures caused by stent-induced tissue hyperplasia.
In this uncontrolled prospective study of 75 patients with achalasia, the newly designed SEMS placement was technically successful in all of the patients, with a postprocedural clinical success rate of 100%. There was no procedure-related mortality and perforation in this study, and all complications were temporary and could be managed without surgical intervention. The SEMS placement led to a 96% clinical remission rate at 1-year followup. Over the >5-year and >-10-year follow-up periods, the clinical remission remained high and effective in 100% and 83.3% of patients, respectively. Our data showed a longer term remission rate than did the results of other published studies with repeated pneumatic dilatations [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . The long-term follow-up results showed that this new stent design provided excellent/good symptomatic relief of achalasia in most of the patients (Fig. 2) . To date, there have been no randomized and prospective clinical trials examining the utility of SEMS placement in the treatment of patients with achalasia. This study was the largest series of SEMS placements reported for managing patients with achalasia; it addressed the role of SEMS in patients with achalasia and demonstrated the long-term safety and effectiveness of temporary SEMS placement as an alternative approach for achalasia. The results were also much better than the previous reports of treating achalasia with the use of SEMS [23, 27, 32, 33] . The difference lies in the fact that the stent we used was a temporary SEMS with a 30-mm diameter and not the commonly used permanent, small-sized stent.
Stent migration was the the most frequent complication for stents placed for benign strictures, ranging from 18.7%-81.8% [23] [24] [25] 35] . Although different types of esophageal SEMS have been used, these stents were of comparatively small diameter and limited radial force, attributes that may have contributed to the more frequent occurrence of migration. In this study, the lower migration rate (5.3%, 4/75) may seem to contribute to the effectiveness of largesized temporary SMES. The suggested mechanism for stent migration in our series was thought to be prevented by the great radial expansile force and friction between the uncovered nitinol wire tube and the esophageal wall. We were able to demonstrate that the stent was resistant to migration in 71 of 75 (94.7%) patients, which indicated that the stent design specialized for cardiac application has exerted great influence on preventing stent migration and might have helped to minimize the likelihood of migration. However, the large-sized SEMS with great radial force may result in another serious complication-perforation.
Perforation is a serious complication found in 1% and 5% of patients with pneumatic dilation in a large series [2] and a systematic review [36] , and the incidence will be high with the increase of the balloon diameter (>30 mm) [1] . In this study, we observed no incidents of esophageal perforation during stent placement. The main reason may be attributed to the characteristic of the SEMS. The stent expanded to its full size within 24 h after placement, and the radial expansile force was generated spontaneously, slowly, and evenly during stent expansion. Thus, the tearing of the cardiac musculature by the stent was slow and gentle, and not like the pneumatic dilation, which can cause acute and sudden tears. The spontaneous, slowly and evenly generated radial expansile force ensured the safety of stent placement and maximally decreased the risk of perforation. As for new strictures induced by the long-term stent placement as mentioned above [23, 27, 32, 33] , there was little likelihood of tissue hyperplasia in our series due to short-term stent placement.
Although the incidence of stent migration, perforation, and new strictures was decreased with the use of the largesized temporary stent, the concomitant complications following stent placement, such as chest pain (38.7%, 28/75), gastro-esophageal reflux (20%, 15/75), and bleeding (12%, 9/75), were a little higher than those following pneumatic dilatation [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] 36] , perhaps because of the radial force and expansion of the stent. These complications were temporary and were alleviated or disappeared spontaneously after removal of the stent, and without additional treatment in most of the cases. As for the possible mechanism for temporary stent placement, we considered that it mainly was attributed to slow tearing of the cardia muscularis with stent expansion. Generally, at body temperature, the stent would gradually expand to the expected diameter within 24 h, and the cardia muscularis was torn slowly and regularly with relatively few scars during stent expansion. Therefore, the incidence of restenosis was very low when it was repaired [31] .
This study, however, had a few limitations. This was a single-center study with no control studies. Therefore, future randomized trials comparing our stent and pneumatic dilatation are needed to compare the efficacy, risk of complications, and recurrent dysphagia, with particular attention given to perforation, reflux, stent migration, and long-term clinical efficacy. We only used subjective criteria to assess the long-term clinical remission or failure after stent treatment in this study; some better scientific assessment, such as esophageal manometry, PH value of the lower esophageal Fig. 3 Curves of clinical remission rate changing over time during 13-year follow-up sphincter, or timed barium esophagram, should be added to more precisely evaluate the long-term clinical outcomes.
In conclusion, despite some temporary complications concomitant with stent placement, our long-term results demonstrate that the newly designed temporary SEMS with a 30-mm diameter was a safe and effective device for treating clinical symptomatic remission of esophageal achalasia. The large-sized temporary SEMS may be an important tool for reducing the risk of complications, such as stent migration, perforation, and new strictures, and it ensured a long-term duration of efficacy, which may justify the use of self-expanding metal stents in benign esophageal achalasia and serve as an alternative or complementary method to pneumatic dilatation.
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